Brazil and Argentina researchers partner to develop Covid-19 vaccine against new variants

Studies in mice with a second-generation vaccine showed encouraging results; the goal is to meet Latin America's demand.

RIO DE JANEIRO, BRAZIL - A new Covid-19 vaccine candidate is being developed by Argentine and Brazilian researchers, searching for a vaccine focused on the new virus variants, such as the P.1, which is present in both countries.

The vaccine, developed in partnership with American biotech Vaxinz, showed positive results in tests with mice, pointing to the production of specific antibodies and immune system response against the novel coronavirus. The goal is to meet the demand for vaccines in Latin America, which still relies on raw materials and alternatives from other continents.

The project began with research by scientists . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?